Tenpoint Therapeutics, Ltd. has appointed Stephen S. Lane, MD, as chief medical officer (CMO). In his new role, Dr. Lane will oversee clinical development strategy, medical affairs, and pharmacovigilance. The company stated in a press release that the appointment supports its efforts to expand development of therapies that target age-related vision conditions.

Dr. Lane brings more than 40 years of experience in ophthalmology, from clinical practice to industry leadership. He most recently served as chief medical officer and Head of Medical Safety at Alcon, Inc. His professional background includes leadership roles across several major ophthalmic organizations, including past President of the American Society of Cataract and Refractive Surgery (ASCRS), former member of the Committee of Secretaries at the American Academy of Ophthalmology (AAO), and board roles with the International Society of Refractive Surgery (ISRS) and the Minnesota Academy of Ophthalmology.

Throughout his career, Dr. Lane has participated in more than 50 clinical trials and delivered more than 400 lectures globally. His contributions to the field also include numerous academic publications, book chapters, and biomedical patents.

In addition to his industry and academic roles, Dr. Lane currently serves as Clinical Professor of Ophthalmology at the University of Minnesota, and chief executive officer of the Holland Foundation for Sight Restoration, which aims to advance ocular stem cell transplantation and corneal surgeon education. OM